Haleon lowers sales outlook after weak cold and flu demand
Health · First reported 29 Oct, 09:00 · Updated 11:30
Haleon cut its sales-growth outlook after weaker demand for cough, cold and flu products. The reports also describe mixed regional and product performance.
- Haleon reduced its expected revenue growth from 3–5% to around 2.5%, citing weaker demand for cough, cold and flu products.
- Haleon reported stronger oral-health sales, including Sensodyne, while its reports described declines in Europe.
- Shares fell sharply in early trading, and the company said it was taking action to improve performance.
Summary written by Lux AI from 2 articles
Key facts
- Revised growth outlook
- Around 2.5%, down from 3–5% previously.
- Quarterly organic revenue growth
- 2.6%, according to Haleon’s chief executive.
- Early trading
- Shares fell more than 11% to 333p, according to City A.M.
- Quarterly revenue
- £2.87bn for the three months to September 30, up 2.5% year on year, according to Insider Media.
Source spectrum
Far left
Left
Lean left
Centre
Lean right
Right
Far right
Unrated
Left 0 · Centre 0 · Right 1 of 1 rated sources · +1 unrated
All coverage
- Haleon shares crater as soft flu demand hits takings29 Oct, 09:00
Coverage over time
LeftCentreRight
Articles per hour since first reported, by side.
Ownership
- Unknown 50% (1)
- Corporation 50% (1)
Share of the 2 sources by owner type.